Dynavax Technologies Corp

  • Earnings Score
  • Moat Score
  • Market Cap $1.67B
  • PE 61
  • Debt -
  • Cash $96.15M
  • EV -
  • FCF $60.16M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$27.31M
EBIT$30.86M
ROE5%
ROA3%
FCF$60.16M
Equity$596.80M
Growth Stability-7%
PE61.23
PEG-1.39
PB2.8
P/FCF27.8
P/S6.03
Price/Cash0.06
Net Margins10%
Gross Margins82%
Op. Margins11%
Earnings CAGR-2%
Sales Growth YoY30%
Sales Growth QoQ-11%
Sales CAGR104%
FCF CAGR-3%
Equity CAGR21%
Earnings Stability0.01
Earnings Growth YoY3K%
Earnings Growth QoQ-60%
Earnings CAGR 5Y-44%
Sales CAGR 5Y53%
FCF CAGR 5Y-37%
Equity CAGR 5Y106%
Earnings CAGR 3Y-35%
Sales CAGR 3Y-35%
FCF CAGR 3Y-45%
Equity CAGR 3Y23%
Market Cap$1.67B
Revenue$277.25M
Assets$986.26M
Cash$96.15M
Shares Outstanding125.45M
Earnings Score6%
Moat Score58%
Working Capital770.31M
Current Ratio10.8
Gross Profit$227.80M
Shares Growth 3y1%
Equity Growth QoQ-12%
Equity Growth YoY-4%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of hepatitis B. Dynavax operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product.

SEC Filings

Direct access to Dynavax Technologies Corp (DVAX) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Dynavax Technologies Corp compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Dynavax Technologies Corp compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -2%
Stability 1%
loading chart...

Dynavax Technologies Corp Discounted Cash Flow

Fully customizable DCF calculator online for Dynavax Technologies Corp.

= $495M
012345678910TV
fcf$60M$58M$57M$55M$53M$52M$50M$49M$47M$46M$45M$447M
DCF$53M$47M$41M$36M$32M$28M$25M$22M$20M$17M$172M
Value$495M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Net Margins-3K%-1K%-29K%-2K%-443%-162%16%41%-3%10%10%
ROA--101%-44%-71%-48%-19%13%30%-0%3%3%
ROE--126%-48%-252%-2K%-128%32%50%-1%5%5%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Debt over FCF----0.74-1.24-1.870----
Debt over Equity---1.621.543.060----
Growth Stability---------7%23%-7%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth-173%-97%2K%330%32%844%64%-68%19%53%
Earnings YoY growth-5%-15%67%-2%-52%-196%306%-102%-527%-44%
Equity YoY growth--52%124%-68%-87%608%279%161%7%-4%106%
FCF YoY growth-15%-32%73%6%-33%-438%-83%74%-38%-37%